Elos Medtech AB (publ) (OM:ELOS B) entered an agreement to acquire Klingel Holding GmbH from IK Partners and Management for an enterprise value of ?370 million on July 28, 2023. The acquisition will be financed through a rights issue in the amount of approximately ?370 million rights issue will be fully guaranteed through a subscription and guarantee undertaking from Elos Medtech?s principal shareholder TA Associates through EM Intressenter AB. The terms and conditions of the rights issue as well as a notice convening an extraordinary general meeting to resolve on the rights issue will be announced at a later date. TA Associates has undertaken to vote in favor of the proposed rights issue at the forthcoming extraordinary general meeting. The deal is subject to conditional on merger clearance and FDI approval required under applicable merger control and trade laws, and the approval by the extraordinary general meeting and successful completion of the rights issue. The transaction is expected to take place during Q4 2023. Jefferies GmbH acted as financial advisor to Klingel Holding GmbH.

Elos Medtech AB (publ) (OM:ELOS B) completed the acquisition of Klingel Holding GmbH from IK Partners and Management on December 6, 2023.